Sclerosing treatment of lymphangiomas with OK-432.
Over a period of seven years, 15 patients (aged from birth to 15 years; median 22 months) with lymphangioma were treated with OK-432; they received a mean of three injections each. Ten received OK-432 as first line treatment; five were treated after surgery (three had a residual lymphangioma after incomplete removal and two had a late recurrence). OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. Seven cases were macrocystic; complete regression was obtained in all. Five cases were microcystic: two had more than 50% regression, and three less than 50%. Three cases were mixed, with both large and microscopic cysts: one had more than 50% regression, and two less than 50%. These last two cases underwent surgery after the sclerosing treatment. The results obtained were excellent in 100% of macrocystic cases; a shrinkage in size was obtained in all microcystic cases. OK-432 is therefore proposed as a first line option for treatment of lymphangiomas.
Luzzatto
C
C
Divisione di Chirurgia Pediatrica, Via Giustiniani 3, 35128 Padova, Italy.
Midrio
P
P
Tchaprassian
Z
Z
Guglielmi
M
M
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008202:Lymphangioma / Q000000981:diagnostic imaging / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use; D011859:Radiography; D015911:Sclerotherapy / Q000379:methods*
D000970:Antineoplastic Agents; D010844:Picibanil